louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01993758: Efficacy of Lower Tourniquet Pressure During Total Knee Arthroplasty
Official title: The Efficacy of Using Lower Tourniquet Pressure During Total Knee Arthroplasty: Comparison With Conventional Tourniquet Pressure Group
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis
Keywords: tourniquet pressure
total knee arthroplasty
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 160
Sex: ALL
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to determine whether the lower tourniquet pressure, which is set by adding 120mmHg (millimeter of mercury) on the systolic blood pressure just before tourniquet inflation, are efficient and safe during total knee arthroplasty, compared with the conventional tourniquet pressure: 150mmHg above the systolic blood pressure before tourniquet inflation.

Detailed description: We will compare the two groups of patients undergoing total knee arthroplasty, which the tourniquet pressure will be set differently: systolic blood pressure plus 120mmHg vs. systolic blood pressure plus 150mmHg, the conventional method, in terms of efficacy and safety.

Eligibility criteria: Inclusion Criteria:

* The patients undergoing total knee arthroplasty

Exclusion Criteria:

* Systolic blood pressure measured at ward \> 200mmHg
* Thigh circumference \> 78cm
* Anesthesia other than spinal anesthesia
* Simultaneous bilateral total knee arthroplasty
* The patients who disagreed the enrollment of this study

Primary outcomes:
measure: Acquisition of bloodless surgical field just after skin incision
timeFrame: just after skin incision during operation
Secondary outcomes:
measure: Failure of acquiring bloodless surgical field during operation
timeFrame: after skin incision through the point of tourniquet deflation
measure: Increasement of tourniquet pressure to acquire bloodless surgical field
timeFrame: after skin incision though the point of tourniquet deflation
measure: Thigh pain on the site of tourniquet application
timeFrame: postoperative 2nd day
measure: Knee pain
timeFrame: postoperative 2nd day
measure: Skin problem on the site of tourniquet application
timeFrame: posteoperative 2nd day
measure: Nerve palsy
timeFrame: within 7 days after surgery
measure: symptomatic venous-thromboembolism
timeFrame: within 7 days after surgery
Other outcomes:
Locations:
city: Seongnam-Si
country: Korea, Republic of
facility: Joint Reconstruction Center, Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Joint Reconstruction Center, Seoul National University Bundang Hospital
name: T K Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim TK, Bamne AB, Sim JA, Park JH, Na YG. Is lower tourniquet pressure during total knee arthroplasty effective? A prospective randomized controlled trial. BMC Musculoskelet Disord. 2019 Jun 4;20(1):275. doi: 10.1186/s12891-019-2636-7.
Clinical trial NCT00519558: Growth Hormone Deficiency in Adults (GHDA)
Official title: Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2007-08-22
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Japan. The aim of this trial is to demonstrate superiority of the effect of NN-220 compared with that of placebo as assessed by the change in percent in truncal fat (kg) from baseline to 24 weeks' treatment (end of treatment) in patients with Growth Hormone Deficiency in Adults (GHDA).


Eligibility criteria: Inclusion Criteria:

* Subjects with diagnosed GHD
* If the subject has a history of treatment of treatment for a tumour of pituitary or peripheral site, two years or more must have passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded
* Appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies

Exclusion Criteria:

* Subject with a history of acromegaly
* Subject with diabetes mellitus
* Subject suffering from malignancy
* Several medical conditions

Primary outcomes:
measure: Percent change in truncal fat (kg) from baseline
timeFrame: at 24 weeks (end of treatment)
Secondary outcomes:
measure: Change in total body fat, total LBM, etc. from baseline to 24 weeks
measure: Lipid-related laboratory tests (total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride)
measure: IGF-I SDS, IGFBP-3 SDS, and IGF-I/IGFBP-3 molar ratio
measure: Adverse events
measure: Clinical laboratory tests
measure: FPG, insulin, and HbA1c
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Chihara K, Kato Y, Shimatsu A, Tanaka T, Kohno H. Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency. Growth Horm IGF Res. 2008 Oct;18(5):394-403. doi: 10.1016/j.ghir.2008.02.002. Epub 2008 Apr 18.
Clinical trial NCT04874558: Ultra-low-dose Chest CT for HHT
Official title: Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Hereditary Hemorrhagic Telangiectasia
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-05-05
Enrollment: 10
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients followed by HHT clinic who are ordered a chest CTA.

Brief summary: This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.


Eligibility criteria: Inclusion Criteria:

* Ages 1 to 17 years
* Diagnosed with positive HHT causing mutations or based on Curacao criteria

Exclusion Criteria:

* Acute respiratory distress
* Unstable cardiovascular status
* Pneumothorax, hemoptysis
* Pulmonary edema
* Pulmonary emboli
* Fractured ribs or other chest trauma
* Recent bronchoscopy
* Lung transplantation

Primary outcomes:
measure: Ultra-low dose images PAVM detection
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Nadir Demirel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03132558: Contrast Induced Acute Kidney in Patients With Acute Stroke
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stroke, Acute
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2017-04-28
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who are suspected with AIS. Non-contrast head CT excludes intracranial hemorrhage. Patients who receieve CTA or CTA+DSA will be included in this study.

Brief summary: Computed tomographic angiography (CTA) is recommended for identifying eligible patient with acute ischemic stroke (AIS) to receieve endovascular treatment. We are going to conduct this prospective corhot study to observe if sequential use contrast in CTA examination and in endovascular treatment will cause acute kidney injury.


Eligibility criteria: Inclusion Criteria:

* All patients who are suspected with AIS.
* Non-contrast head CT excludes intracranial hemorrhage.

Exclusion Criteria:

* Lacking of pre-CTA Creatinine
* Lacking of post-angiography Creatinine with 24-48 hours

Primary outcomes:
measure: Creatinine
timeFrame: within 24h to 48h
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
References:
citation: Jia ZY, Wang SX, Zhao LB, Cao YZ, Shi HB, Liu S. Risk of Acute Kidney Injury with Consecutive, Multidose Use of Iodinated Contrast in Patients with Acute Ischemic Stroke. AJNR Am J Neuroradiol. 2019 Apr;40(4):652-654. doi: 10.3174/ajnr.A5959. Epub 2019 Jan 24.
Clinical trial NCT01161758: Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals
Official title: A Crossover Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Keywords: physical therapy
pain threshold
electromyography
musculoskeletal manipulation
neck muscles
Lead sponsor: Curtin University
Sponsor class: OTHER
First posted: 2010-07-14
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Passive accessory cervical mobilization is widely used as a clinical approach to the management of musculoskeletal pain of spinal origin. The purpose of the study is to determine if passive cervical mobilization can improve motor function in situations where motor performance is not impaired by the presence of pain.

Detailed description: Cervical mobilization has been shown to elicit effects on pain perception, autonomic function and motor function in subjects who experience musculoskeletal pain. The improvement in motor function may be a direct effect of the treatment or secondary to a hypoalgesic effect. This study aims to demonstrate whether it is possible to alter motor function following joint mobilization, in situations where motor performance is not impaired by pain.

Eligibility criteria: Inclusion Criteria:

* No history of neck or back pain over the last six months
* Without any previous experience with spinal manual therapy techniques

Exclusion Criteria:

* History of musculoskeletal or rheumatologic conditions
* Any kind of spinal surgery
* Dizziness
* Previous trauma to the cervical spine
* Neurological signs or symptoms

Primary outcomes:
measure: Electromyography of sternocleidomastoid muscle.
timeFrame: Pre intervention (baseline) and 1 minute post intervention
Secondary outcomes:
measure: Pressure pain threshold
timeFrame: Pre intervention (baseline) and 1 minute post intervention
Other outcomes:
Locations:
Study officials:
affiliation: The University of Queensland
name: Benjamin Soon Tze Chin, MManipTher
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Queensland
name: Annina Schmid, MManipTher
role: PRINCIPAL_INVESTIGATOR
affiliation: Curtin University
name: Elias Fridriksson, MManipTher
role: PRINCIPAL_INVESTIGATOR
affiliation: Curtin University
name: Philip Cheong, MManipTher
role: PRINCIPAL_INVESTIGATOR
affiliation: Curitn University of Technology
name: Elisabeth Gresslos, MManipTher
role: PRINCIPAL_INVESTIGATOR
affiliation: Curtin University
name: Anthony Wright, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04150458: Fluorocholine PET/CT Basket Trial
Official title: Performance of 18F-Fluorocholine Positron Emission Tomography With Computed Tomography in Patients With 18F-Fluorocholine-avid Lesions: A Basket Trial
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE3
Conditions: Fluorocholine PET/CT
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Sponsor class: OTHER
First posted: 2019-11-04
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a single-arm, open-label, phase III trial in up to 2000 patients with known or suspected benign or malignant tumors which are known or suspected to be 18F-fluorocholine-avid.

Patients will receive regular standard clinical care. The only study-specific procedure will be the administration of 18F-fluorocholine followed by a PET/CT scan.

Diagnostic accuracy of 18F-fluorocholine PET/CT will be captured versus a composite clinical, radiological and histopathological standard of truth at follow-up.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Under referring physician's care
* Able to understand and provide written informed consent
* Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine (or prone) for up to 30 minutes and tolerating intravenous cannulation for injection
* Known or suspected benign or malignant tumor which is known or suspected to be 18F-fluorocholine-avid as per current medical literature

Exclusion Criteria:

* Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
* Exceeding the safe weight limit of the PET/CT bed (usually approximately 400 lbs.) or cannot fit through the PET/CT bore (usually approximately 70 cm diameter)
* Unmanageable claustrophobia

Primary outcomes:
measure: Diagnostic accuracy of Fluorocholine PET/CT
timeFrame: 1 day
Secondary outcomes:
measure: Incidence of treatment-emergent adverse events following Fluorocholine PET/CT
timeFrame: 30 minutes
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
Study officials:
affiliation: Jewish General Hospital
name: Stephan Probst, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06813196: Forest Bathing Intervention for Persons Living with Dementia and Family Carers
Official title: Forest Bathing Intervention for Persons Living with Dementia and Family Carers: a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dementia
Caregiver Mental Health
Keywords: Forest bathing
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Hong Kong Young Women's Christian Association
First posted: 2025-02-06
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study assessed the feasibility and acceptability of a forest bathing intervention for people living with dementia and their family carers, and examined its effectivness on care burden and quality of life by comparing to an art activty programme as control group.


Eligibility criteria: Inclusion Criteria:

* For family careivers:
* taking care of a family member living with dementia in the community,
* For people living with dementia:
* Clinical diagnosis of mild to moderate dementia

Exclusion Criteria:

* For both:
* Unable to communicate in Chinese or Cantonese
* Unable to participate meaningfully in group activities due to intellectual disability, visual impairment, hearing impairment, or other health conditions, were excluded.

Primary outcomes:
measure: Change in Caregiver's Care Burden measured by 12-item version of Zarit Burden Interview (ZBI-12)
timeFrame: Baseline and 6 weeks
measure: Change in Caregiver's Depressive Symptoms measured by the Depression subscale of Hospital Anxiety and Depression Scale (HADS-D)
timeFrame: Baseline and 6 weeks
measure: Change in Caregiver's Anxiety Symptoms measured by the Anxiety subscale of Hospital Anxiety and Depression Scale (HADS-A)
timeFrame: Baseline and 6 weeks
Secondary outcomes:
measure: Change in Caregiver's Positive Aspect of Caregiving measured by the Positive Aspect of Caregiving Scale (PACS)
timeFrame: Baseline and 6 weeks
measure: Change in Caregiver's Caregiving Self-Efficacy measured by the Revised Scale for Caregiving Self-Efficacy (CSE-R)
timeFrame: Baseline and 6 weeks
measure: Change in Caregiver's Health-related Quality of Life measured by the Visual Analogue Scale of EuroQol 5-dimension 5-level (EQ5D5L VAS)
timeFrame: Baseline and 6 weeks
measure: Change in Neuropsychiatric Symptoms of Person Living with Dementia measured by the Neuropsychiatric Inventory - Questionnaire (NPI-Q)
timeFrame: Baseline and 6 weeks
measure: Change in Health-related Quality of Life of Person Living with Dementia measured by the Visual Analogue Scale of EuroQol 5-dimension 5-level (EQ5D5L VAS)
timeFrame: Baseline and 6 weeks
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The University of Hong Kong
Study officials:
affiliation: The University of Hong Kong
name: Chak Pui Jacky Choy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02585596: A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.
Official title: A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH23537 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Periodontitis
Lead sponsor: Yuhan Corporation
Sponsor class: INDUSTRY
First posted: 2015-10-23
Enrollment: 275
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy and the safety of YH23537 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.

Detailed description: at screening visit, at least existing 18 teeth,Mild/moderate/severe periodontitis patients diagnosed with chronic periodontitis according to the CDC / AAP (Center for Disease Control / American Academy for Periodontology) periodontitis classification (2012).

Eligibility criteria: Inclusion Criteria:

* Subjects must be 19 years of age or older
* Have at least 18 natural teeth
* have been diagnosed with chronic periodontitis
* have been diagnosed Mild/Moderate/Severe periodontitis with according to CDC / AAP periodontal classification (2012))
* Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

* Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to 4 weeks after the last dose of investigational product.
* Pregnant or lactating females
* Systemic diseases such as diabetes and hypertension
* Patients who take Anticoagulants or Antiplatelet Agents
* Continually use for phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month
* Patients who received periodontal treatment within the last 6 months
* Patients who have malignant tumor
* History of positive serologic evidence of current infectious liver disease including HbsAg, or anti-HCV.
* Patients with mental retardation and dementia

Primary outcomes:
measure: Change in probing pocket depth (PD)
timeFrame: baseline, 4weeks, 8week, 12weeks
Secondary outcomes:
measure: Change in Clinical attachment level (CAL)
timeFrame: baseline, 4weeks, 8week, 12weeks
measure: Change in Bleeding on probing(BOP)
timeFrame: baseline, 4weeks, 8week, 12weeks
measure: Change in Gingival recession(GR)
timeFrame: baseline, 4weeks, 8week, 12weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Incheol Rhyu
Study officials:
affiliation: Seoul National University Hospital
name: Incheol Rhyu, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00426296: SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Official title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: HIV Infections
Lipodystrophy
Keywords: HIV
Reyataz
atazanavir
Norvir
ritonavir
Boosted
Lipodystrophy
Treatment Experienced
Lead sponsor: Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2007-01-24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Detailed description: Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry

Eligibility criteria: Inclusion Criteria:

* Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
* Viral load \<50 copies/ml

Exclusion Criteria:

* Viral load \>50 copies/ml
* Having taken more than one antiretroviral regimen

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: Whitman-Walker Clinic
state: District of Columbia
Study officials:
affiliation: Whitman-Walker Clinic
name: Richard A Elion, MD
role: PRINCIPAL_INVESTIGATOR
References: